CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective:

* Pathological complete response (ypT0N0) rate

Secondary objectives:

* Histopathological R0 resection rate
* Pathological downstaging (ypT0-T2N0) rate
* One month surgical complication rate
* Predictive value of pre-operative MRI for surgical, pathological and clinical outcomes
* Safety
* Local and distant recurrence rates
* Progression-free survival
* Overall survival
Rectal Neoplasms
DRUG: Oxaliplatin, capecitabine, radiotherapy
MRI staging and TME surgery, within 4 - 6 weeks after completion XELOX-RT
Measure safety - NCI-CTC version 2, from baseline to end of study
Primary objective:

* Pathological complete response (ypT0N0) rate

Secondary objectives:

* Histopathological R0 resection rate
* Pathological downstaging (ypT0-T2N0) rate
* One month surgical complication rate
* Predictive value of pre-operative MRI for surgical, pathological and clinical outcomes
* Safety
* Local and distant recurrence rates
* Progression-free survival
* Overall survival